Nichols & Pratt Advisers LLP MA Has $19.58 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Nichols & Pratt Advisers LLP MA grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 40,359 shares of the medical research company’s stock after buying an additional 11,157 shares during the period. Thermo Fisher Scientific accounts for about 1.2% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 25th largest position. Nichols & Pratt Advisers LLP MA’s holdings in Thermo Fisher Scientific were worth $19,575,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Callan Family Office LLC lifted its stake in shares of Thermo Fisher Scientific by 1.9% in the third quarter. Callan Family Office LLC now owns 16,345 shares of the medical research company’s stock valued at $7,928,000 after buying an additional 312 shares during the period. Simmons Bank raised its holdings in Thermo Fisher Scientific by 9.3% in the 3rd quarter. Simmons Bank now owns 8,764 shares of the medical research company’s stock valued at $4,251,000 after acquiring an additional 745 shares in the last quarter. Keeler Thomas Management LLC lifted its position in shares of Thermo Fisher Scientific by 5.0% in the 3rd quarter. Keeler Thomas Management LLC now owns 2,036 shares of the medical research company’s stock worth $987,000 after acquiring an additional 97 shares during the period. Heritage Investors Management Corp increased its position in shares of Thermo Fisher Scientific by 0.3% during the third quarter. Heritage Investors Management Corp now owns 56,761 shares of the medical research company’s stock valued at $27,530,000 after purchasing an additional 174 shares during the period. Finally, Peterson Wealth Services raised its stake in shares of Thermo Fisher Scientific by 1,043.6% in the third quarter. Peterson Wealth Services now owns 4,197 shares of the medical research company’s stock valued at $2,036,000 after purchasing an additional 3,830 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.6%

TMO stock opened at $582.07 on Tuesday. The business has a fifty day moving average price of $593.88 and a 200 day moving average price of $539.86. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The stock has a market capitalization of $218.69 billion, a price-to-earnings ratio of 32.81, a P/E/G ratio of 3.82 and a beta of 0.93.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business earned $6.10 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has initiated a share repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.70%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 32,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the sale, the chief operating officer directly owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This represents a 32.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares of the company’s stock, valued at $8,085,564.90. This trade represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 124,517 shares of company stock valued at $72,363,568 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TMO. Stifel Nicolaus boosted their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. TD Cowen lowered their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research note on Friday. Finally, KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price for the company in a research report on Sunday, December 7th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.